SLC5A2 and Hyperglycemia: Bouchi et al. (2021) found that while intensive exercise did not prevent the loss of fat-free mass during SGLT2 inhibitor therapy, it significantly enhanced abdominal fat reduction, potentially leading to better management of hyperglycemia and chronic inflammation compared to dapagliflozin alone [19].